4Q Revenues: $10.2 billion (+4%)
4Q Earnings: $674.8 million (+18%)*
FY Revenues: $42.0 billion (+6%)
FY Earnings: $7.5 billion (+37%)*
Comments: Pharmaceutical sales were $9.0 billion (+3%) in 4Q09 and $37.0 billion(+4%) for FY09. Sales of Lantus were $1.1 billion in the quarter (+17%). Sales of Apidra were up 30% in the quarter to $53 million. Lovenox sales were up 8% to $1.1 billion. Taxotere sales were $763.6 million, up 4%. Sales of Eloxatin were down 81% to $96.0 million, due to generic competition. The company launched Multaq in the quarter with sales of $17.2 million. Vaccines sales were up 19%, with flu vaccine sales of $1.5 billion, including $630.4 million of A/H1N1 sales. Pentacel sales reached $488.5 million in the U.S. Exchange rates had an unfavorable effect of 5% in the quarter.
*Adjusted net income
